Skip to content
November 27, 2024

Investment information for the new generation

Search

Pharmaceuticals

Drug science is all about timing. You can either take a preexisting molecule, which has benefits for alternative indications rather than what it’s originally on shelves for, and you…
BetterLife is a biotechnology company that develops and commercializes psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. BetterLife. has…
In this episode, we look at BetterLife Sciences (BETR.C), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders. We check out their…
BetterLife Pharma (BETR.CN) is a Biotech company focused on developing second generation psychedelic compounds and nutraceuticals. Their products will address the unmet needs in the mental health, wellness and…
Acasti Pharma (ACST.V) announced today that it has initiated its planned pharmacokinetic (PK) bridging study to evaluate the bioavailability of intravenous (IV) GTX-104 compared to oral nimodipine capsules in…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release.   If you’re not entirely sure what an ETF…
Numinus Wellness (NUMI.V) announced today that it has closed its acquisition of the Neurology Centre of Toronto (NCT). “NCT by Numinus represents an important paradigm shift in neurologic care…By…
Sixth Wave (SIXW.C) announced today that it has received additional grant funding for its joint research project with York University. “The grant provides the Company a significant opportunity to…
In this episode, we take to look at Element Nutritional Sciences (ELMT.C) a nutraceutical company that uses plant-based technology and extensive nutritional research to create health-driven products for customers….
Protagonist Therapeutics (PTGX.Q) announced the receipt of verbal communication from the U.S. Food and Drug Administration (FDA) that the Company’s clinical studies for rusfertide have been placed on a…